Brief: Bone Biologics Reports Progress With NB1 Clinical Program
01/03/2024 13:12
March 1 (Reuters) - Bone Biologics Corp BBLG.O :
* BONE BIOLOGICS: REPORTS PROGRESS WITH ADVANCING PRODUCT
CANDIDATE NB1 INTO HUMAN CLINICAL TESTING FOR SPINAL FUSION
* BONE BIOLOGICS: THREE HOSPITAL SITES ENGAGED TO
PARTICIPATE IN
PILOT CLINICAL TRIAL
Source text for Eikon: ID:nBw94f9wGa
Further company coverage: BBLG.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Bone Biologics
See all newsBone Biologics Corp expected to post a loss of 39 cents a share - Earnings Preview
Brief: Bone Biologics Extends Rhnell-1 Shelf Life To 24 Months
Brief: Bone Biologics CEO Issues Letter To Stockholders Highlighting Company Update And Outlook
Bone Biologics Corp expected to post a loss of 53 cents a share - Earnings Preview
Bone Biologics Corp expected to post a loss of 58 cents a share - Earnings Preview